Pancreatic Cancer Research

ResearcherChang Gung UniversityActive in the last 2 years

Yu‐Shin Hung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6976-5894; OpenAlex author ID A5088734348. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2018: 2 papers · 2019: 5 papers · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 12

  1. Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jfma.2026.01.057↗
  2. The efficacy and safety profile of third-line treatment in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.01.012↗
  3. Validation of a Prognostic Nomogram for Patients with Metastatic Pancreatic Cancer Treated with Nanoliposomal Irinotecan as Second-Line Therapy. Co-author DOI 10.1177/10732748251333040↗
  4. External validation of the Besançon nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience… Co-author DOI 10.1016/j.pan.2019.11.001↗
  5. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemothera… Co-author DOI 10.1111/jgh.14926↗
  6. Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan. Co-author DOI 10.1002/cam4.2094↗
  7. Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic … Co-author DOI 10.1002/cam4.2254↗
  8. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Co-author DOI 10.1002/cam4.2483↗
  9. Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Co-author DOI 10.3390/cancers11010057↗
  10. Lung Metastases in Patients with Stage IV Pancreatic Cancer: Prevalence, Risk Factors, and Survival Impact. Co-author DOI 10.3390/jcm8091402↗
  11. Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy. Co-author DOI 10.3390/cancers10110432↗
  12. Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with E… Co-author DOI 10.3390/cancers10120501↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wen‐Chi Chou · 12 shared papers, 2018–2026 · strength 1.76
  2. Yen‐Yang Chen · 10 shared papers, 2018–2026 · strength 1.30
  3. Jen‐Shi Chen · 8 shared papers, 2018–2026 · strength 1.09
  4. Tai‐Jan Chiu · 3 shared papers, 2025–2026 · strength 0.91
  5. Pei‐Hung Chang · 9 shared papers, 2018–2020 · strength 0.85
  6. Chi-Chen Lan · 2 shared papers, 2025–2026 · strength 0.54
  7. Chieh-Ying Chang · 1 shared paper, 2026 · strength 0.29
  8. Pei‐Wei Huang · 3 shared papers, 2019 · strength 0.28
  9. Keng-Hao Liu · 2 shared papers, 2019–2020 · strength 0.19
  10. Ching‐Fu Chang · 2 shared papers, 2019 · strength 0.19
  11. Shao‐Ming Yu · 1 shared paper, 2020 · strength 0.11
  12. Chih–Chung Hsu · 1 shared paper, 2020 · strength 0.11
  13. Shu‐Hui Lee · 1 shared paper, 2019 · strength 0.09
  14. Hsiang‐Lan Lai · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.